Target Audience
- Researchers and scientists familiar with the fundamentals of next-generation sequencing (NGS), genomic analysis, and molecular biology who want to understand how these technologies are being applied across the life sciences industry.
- Scientists, engineers, and business development professionals interested in the competitive landscape and future direction of genomics-related companies.
- Readers seeking to understand Thermo Fisher Scientific's business strategy and the broader transition from genomics to proteomics, multiomics, and clinical applications.
Summary
- Thermo Fisher Scientific is evolving from a supplier of laboratory instruments and reagents into an integrated life sciences company supporting drug discovery, molecular diagnostics, clinical trials, and pharmaceutical manufacturing.
- In NGS, the company is emphasizing automated clinical workflows and faster turnaround times through Ion Torrent, Genexus, and Oncomine, rather than competing solely on high-throughput sequencing performance.
- Its acquisition of Olink in 2024 strengthened its position in large-scale proteomics and created opportunities to integrate genomic, proteomic, and clinical data.
- The acquisition of Clario in 2026 reflects a broader strategy to expand clinical trial data capabilities and connect research, clinical development, and pharmaceutical manufacturing.
- Understanding Thermo Fisher's future competitiveness requires looking beyond sequencing instruments to its ability to translate genomic information into biological insights, diagnostics, drug discovery, and pharmaceutical development.
1. Thermo Fisher Scientific's Current Position and Overall Strategy
Thermo Fisher Scientific (hereafter, Thermo Fisher) is evolving from a manufacturer of analytical instruments and reagents into an integrated life sciences platform company supporting drug discovery, molecular diagnostics, clinical trials, and pharmaceutical manufacturing.
From a genomics perspective, one particularly important point is that the company's growth strategy is not necessarily centered on increasing its market share in next-generation sequencing (NGS) instruments.
Instead, the competitive landscape is shifting along several dimensions.
-
From sequencing instrument performance to clinical workflow optimization
Automation, shorter turnaround times, and standardized workflows are becoming increasingly important, particularly in cancer genomic testing.
-
From genomics alone to multiomics
Combining Olink's high-multiplex protein analysis technology with Orbitrap mass spectrometry creates new opportunities for molecular phenotyping of diseases.
-
From selling research tools to integrating the pharmaceutical development value chain
Research reagents, biopharmaceutical manufacturing, contract research organization (CRO) services, and clinical trial data businesses are becoming increasingly interconnected.
-
From individual product advantages to long-term customer relationships
Reagents, consumables, services, and data analysis solutions create opportunities to generate recurring revenue throughout the customer's research and development activities.
Two acquisitions illustrate this transformation particularly well: Olink in 2024 and Clario in March 2026.
The former strengthened Thermo Fisher's capabilities in proteomics, while the latter expanded its ability to collect and analyze clinical trial endpoint data. The Clario acquisition involved approximately $8.875 billion in cash consideration. [1][2]
Taken together, these developments suggest that Thermo Fisher is positioning itself not simply as a company that "reads genomes," but as an infrastructure provider that connects genomic information to disease biology, diagnostics, drug discovery, and pharmaceutical development.
2. Company Scale and Financial Performance
2.1 Full-Year 2025 and Third-Quarter 2026 Results
First, let's examine Thermo Fisher's current scale and recent financial performance.
| Metric | Result |
|---|---|
| FY2025 revenue | $44.56 billion |
| FY2025 revenue growth | +3.9% year over year |
| Q3 2026 revenue | $12.14 billion |
| Q3 2026 revenue growth | +9% year over year |
| Q3 2026 organic revenue growth | +6% |
| Q3 2026 adjusted operating margin | 24.5% |
| Prior-year adjusted operating margin | 23.3% |
| Q3 2026 adjusted earnings per share (EPS) | $6.68 |
| Adjusted EPS growth | +15% year over year |
In its third-quarter results announced on October 21, 2026, Thermo Fisher reported revenue growth of 9% year over year, with organic revenue growth of 6% after adjusting for factors such as acquisitions and foreign exchange movements. [3]
The adjusted operating margin also improved from 23.3% in the prior-year period to 24.5%.
This performance suggests that the company's diversified business model, which is not solely dependent on the research instrument market, is helping support revenue growth and profitability.
2.2 Business Portfolio
Thermo Fisher operates through four major business segments.
| Business segment | FY2025 Revenue |
|---|---|
| Laboratory Products and Biopharma Services | $23.984 billion |
| Life Sciences Solutions | $10.374 billion |
| Analytical Instruments | $7.554 billion |
| Specialty Diagnostics | $4.676 billion |
Note: These figures represent segment revenues before intersegment eliminations. Consequently, their sum differs from consolidated revenue. [4]
For genomics researchers, Life Sciences Solutions may be the most familiar business segment, as it includes brands and technologies such as Applied Biosystems, Invitrogen, and Ion Torrent.
However, Laboratory Products and Biopharma Services accounts for a substantially larger portion of the company's overall business.
This segment includes laboratory products and services supporting biopharmaceutical development and manufacturing.
This distinction is important.
Winning the competition in NGS instrument sales is not necessarily a prerequisite for Thermo Fisher's overall growth.
2.3 Long-Term Financial Targets
At its Investor Day in May 2026, Thermo Fisher's management presented the following long-term financial targets: [5]
- Organic revenue growth: approximately 7% annually
- Adjusted EPS growth: low teens annually
Its growth strategy emphasizes strengthening existing businesses, acquiring new capabilities, and improving productivity through its Practical Process Improvement (PPI) system.
These figures are management targets rather than guaranteed future results.
3. Competitive Position in Genomics: How Does Thermo Fisher Differ from Illumina?
Any assessment of Thermo Fisher's genomics business inevitably involves a comparison with Illumina.
However, comparing the two companies solely on sequencing performance risks overlooking their different strategic priorities.
3.1 Where Does Ion Torrent Compete?
Thermo Fisher owns Ion Torrent, a semiconductor-based sequencing technology.
One of its representative products is the Ion Torrent Genexus System.
Ion Torrent Genexus System
Genexus integrates and automates workflows spanning nucleic acid extraction, library preparation, sequencing, variant analysis, and reporting.
According to the manufacturer's published specifications, the system can deliver results in as little as 24 hours. [6]
Illumina's competitive strengths include large-scale sequencing, a broad application portfolio, and an extensive ecosystem.
By contrast, Thermo Fisher has opportunities to differentiate itself through standardized clinical genomics workflows capable of rapidly and reproducibly processing small to medium-sized sample batches.
The differences can be summarized as follows.
| Competitive dimension | Illumina | Thermo Fisher |
|---|---|---|
| Primary sequencing technology | Sequencing by synthesis | Ion Torrent semiconductor sequencing |
| Core strengths | WGS, WES, broad NGS applications | Targeted NGS, clinical workflow automation |
| Key customer value | Cost efficiency and data quality in large-scale analysis | Short turnaround times, reduced hands-on work, standardization |
| Particularly relevant markets | Large-scale genomic research and clinical genomics | Oncology molecular profiling and hospital-based testing |
| Strategic challenges | Declining sequencing prices and increasing competition | Maintaining NGS competitiveness and market differentiation |
Note: This table compares technological and strategic positioning. It does not represent a ranking of sequencing market shares in 2026.
3.2 Why Oncomine and Genexus Matter
Consider molecular profiling in lung cancer.
Clinically relevant biomarkers include EGFR, BRAF, MET exon 14 skipping, ALK, ROS1, RET, and NTRK, requiring assessment of alterations involving both DNA and RNA.
In this context, the number of reads generated or cost per gigabase is not necessarily the most important performance metric.
For routine clinical testing, other factors become critical:
- Successful analysis of small FFPE tissue samples
- Ability to detect SNVs, indels, CNVs, and gene fusions within a unified workflow
- Turnaround time (TAT) from sample receipt to reporting
- Cost efficiency for laboratories processing small batches
- Dependence on specialized bioinformatics personnel
- Compatibility with in vitro diagnostic (IVD) requirements, quality management, and laboratory operations
The Oncomine Precision Assay targets 50 genes and supports the analysis of multiple classes of genomic alterations.
Thermo Fisher highlights its low nucleic acid input requirements and rapid reporting capabilities. [7]
During the third quarter of 2026, the company also introduced the Ion 560 Chip for the Ion GeneStudio S5 system.
According to Thermo Fisher, the new chip approximately doubles sequencing capacity compared with its predecessor. [3]
This development suggests that the company is not abandoning Ion Torrent. Instead, it continues to improve productivity and sample-processing capacity across its installed instrument base.
3.3 Evaluating Thermo Fisher's NGS Strategy
Rather than assuming Thermo Fisher must regain leadership in high-throughput whole-genome sequencing, a more plausible strategy is to improve the completeness and efficiency of sample-to-answer workflows in clinical laboratories.
However, assessing competitiveness across the broader NGS market requires comparisons beyond Illumina.
Element Biosciences, MGI, Oxford Nanopore, and PacBio are also important competitors.
These technologies should be evaluated based on application-specific performance and total cost of ownership.
In particular, short-read and long-read sequencing technologies have different characteristics and applications.
Therefore, ranking sequencing platforms using a single performance metric would be inappropriate.
4. The Most Significant Strategic Shift: Olink and Proteomics
Thermo Fisher's acquisition of Olink in 2024 represents an important turning point in its strategy related to genomics and molecular profiling.
4.1 Strategic Importance of the Olink Acquisition
In July 2024, Thermo Fisher completed its acquisition of Olink at an enterprise valuation of approximately $3.1 billion. [8]
Olink is a next-generation proteomics company whose core technology is the Proximity Extension Assay (PEA).
Through this acquisition, Thermo Fisher strengthened its capabilities in highly multiplexed protein analysis, complementing its existing genomics and mass spectrometry businesses.
Why is this acquisition important?
Because there is growing interest in understanding biological states that cannot be adequately characterized using genomic information alone.
Proteins provide information about disease activity, biological responses, and molecular phenotypes that may not be directly inferred from DNA sequence data.
4.2 Why PEA Is Particularly Compatible with Genomics
Olink's core technology, PEA, converts antibody-binding events into DNA-based readouts.
The basic principle can be summarized as follows.
- Two antibodies bind to the same target protein.
- DNA oligonucleotides attached to the antibodies are brought into proximity.
- An extension reaction generates a DNA product corresponding to the target protein.
- The resulting DNA products are quantified using qPCR or NGS, providing information about protein abundance.
In other words, PEA transforms protein-binding events into DNA amplification and quantification signals.
Its significance extends beyond high multiplexing.
PEA allows proteomics measurements to connect with DNA-based digital counting systems, including NGS.
From a genomics perspective, this is more than just another protein quantification method.
For example, researchers attempting to understand disease mechanisms associated with GWAS loci can integrate several layers of molecular information.
GWAS / WGS / eQTL
↓
pQTL / Protein expression
↓
Mendelian randomization and causal inference
↓
Target identification and biomarker validation
This approach can help connect genetic variation, protein abundance, and disease-associated biological mechanisms.
However, inferring causality from pQTL data requires careful validation.
Important considerations include:
- Horizontal pleiotropy
- Linkage disequilibrium
- Colocalization analysis
- Assay-specific artifacts
A particularly important issue is that coding variants affecting antibody binding may produce apparent differences in measured protein levels without corresponding changes in actual protein abundance.
These effects must be distinguished from genuine biological associations.
4.3 Olink and Orbitrap Are Complementary Rather Than Directly Competing Technologies
In addition to Olink, Thermo Fisher owns Orbitrap-based mass spectrometry technologies.
Both are used in proteomics, but their roles are not identical.
| Technology | Main characteristics |
|---|---|
| Olink PEA | Suitable for standardized, highly multiplexed measurement of known target proteins across large sample cohorts |
| Orbitrap LC-MS/MS | Strong capabilities in exploratory analysis, including broad protein and peptide identification, sequence information, and post-translational modifications |
Combining these approaches enables a research workflow spanning discovery, validation, and clinical translation.
Discovery
LC-MS/MS can be used to identify candidate proteins and associated biological pathways.
Large-cohort validation
PEA can measure selected proteins across large numbers of samples.
Clinical translation
Known biomarkers can then be evaluated for reproducibility and clinical utility.
However, relative quantification using PEA and peptide-based measurements using LC-MS/MS do not necessarily measure exactly the same molecular species.
Cross-platform validation must therefore consider isoforms, proteoforms, post-translational modifications (PTMs), analytical sensitivity, and batch effects.
4.4 A Major Development in 2026: Precure with Mayo Clinic
On September 15, 2026, Mayo Clinic announced Precure, with Thermo Fisher as a founding partner. [9]
The initiative aims to integrate proteomics, genomics, and longitudinal clinical information using data derived from more than one million patient samples.
Its objective is to identify biological changes that occur before disease symptoms become apparent and connect these findings to disease understanding, diagnostics, and therapeutic development.
This illustrates that Thermo Fisher's proteomics strategy extends beyond selling instruments and reagents.
The company is exploring opportunities involving large-scale cohort data, disease biology, biomarker discovery, and future diagnostic and drug discovery applications.
However, translating research findings into clinically useful early-detection tests requires substantial validation.
Key requirements include:
- Independent replication in external cohorts
- Assessment of positive predictive value in populations with realistic disease prevalence
- Validation of longitudinal predictive performance
- Demonstration that clinical interventions based on the biomarkers improve patient outcomes
These will be important areas to monitor over the next five years.
5. Vertical Integration Across Drug Discovery, Clinical Development, and Manufacturing
Evaluating Thermo Fisher solely through the genomics market would underestimate the breadth of its business strategy.
The company has capabilities to generate revenue at multiple stages of pharmaceutical research, development, and manufacturing.
5.1 Thermo Fisher Across the Pharmaceutical Value Chain
Its business portfolio can be mapped onto the pharmaceutical development process as follows.
| Stage | Primary activities | Relevant products, brands, and services |
|---|---|---|
| 1. Target discovery and disease biology | Identification of disease-associated molecular targets | Applied Biosystems, Invitrogen, Olink, Orbitrap |
| 2. Preclinical research and biomarker discovery | Molecular analysis and candidate evaluation | Reagents, analytical instruments, sample preparation, multiomics |
| 3. Clinical trials and data collection | Trial management and clinical data acquisition and analysis | PPD, Clario |
| 4. Pharmaceutical manufacturing and process development | Process development and biopharmaceutical production | Patheon, Gibco, bioprocessing products |
| 5. Quality control and product supply | Quality assessment and product supply | Analytical instruments, reagents, laboratory products, services |
This does not mean that all stages are already connected through a single integrated product.
Rather, Thermo Fisher has products and services relevant to multiple stages of the pharmaceutical value chain.
5.2 What the Clario Acquisition Reveals About Its Strategy
On March 24, 2026, Thermo Fisher completed its acquisition of Clario.
The transaction involved $8.875 billion in cash consideration, with the possibility of additional payments depending on factors such as performance. [2]
Clario specializes in collecting and analyzing clinical trial endpoint data.
Its services cover data generated by devices, clinical trial sites, and study participants.
An important point is that Clario is not an NGS company.
Thermo Fisher is investing not only in technologies that generate genomic information, but also in clinical trial data, clinical evaluation, therapeutic response assessment, and pharmaceutical development capabilities.
In the future, integrating several categories of data could become increasingly important.
| Data category | Main information |
|---|---|
| Genomics | Genetic alterations associated with treatment response or disease risk |
| Transcriptomics / Proteomics | Molecular states and drug-induced biological changes |
| Clinical endpoints | Response rates, progression-free survival (PFS), overall survival (OS), patient-reported outcomes |
| Real-world data | Information related to effectiveness and safety after regulatory approval |
In oncology, immune-mediated diseases, and rare diseases, relationships between molecular biomarkers and clinical outcomes can significantly influence clinical trial design and patient stratification.
However, this does not mean that genomic and proteomic data are already integrated with Clario's clinical trial data in a single operational platform.
At present, this should be viewed as a potential strategic synergy rather than an established integrated capability.
6. Growth Opportunities Over the Next Three to Five Years
Based on Thermo Fisher's business portfolio, publicly stated management priorities, and technological trends, several growth areas warrant attention over the next three to five years.
| Area | Assessment of growth potential | Key areas to watch |
|---|---|---|
| Large-scale proteomics | Very high | Olink, pQTL, large cohorts |
| Clinical genomics | High | Genexus, Oncomine, hospital-based NGS |
| Biopharmaceutical manufacturing | High | Gibco, Patheon, filtration and purification |
| Clinical trial data | High | PPD, Clario, digital endpoints |
| Mass spectrometry and structural biology | High | Orbitrap, cryo-EM, drug discovery |
| NGS instruments for large-scale WGS | Uncertain | Technology and pricing competition |
Note: These are qualitative assessments based on public information and technological trends. They are not company-issued growth forecasts for individual businesses.
Three developments appear especially important: the industrialization of large-scale human proteomics, decentralized molecular diagnostics, and AI-driven improvements in research and drug development.
6.1 Industrialization of Large-Scale Human Proteomics
In genomics, the long-term decline in DNA sequencing costs enabled large-scale population studies.
A similar transformation could occur in proteomics as measurements become more standardized and scalable.
Proteomics could provide increasingly useful information about disease states, disease progression, environmental effects, and treatment responses that cannot be fully explained by genomic data alone.
Thermo Fisher is positioned to benefit from this trend through its ownership of Olink, Orbitrap, and existing genomic analysis products.
However, competition is not limited to Olink versus conventional mass spectrometry.
Other affinity-based technologies, such as SomaScan, and increasingly high-throughput data-independent acquisition mass spectrometry (DIA-MS) also play important roles.
PEA will not necessarily be superior for every research application.
6.2 Decentralization and Automation of Molecular Diagnostics
Two models of advanced genomic testing are likely to coexist.
One relies on centralized, high-throughput reference laboratories.
The other brings testing closer to hospitals and clinical facilities.
Thermo Fisher's Genexus platform is strategically aligned with the second model.
In hospital-based molecular diagnostics, factors such as ease of operation, support for small sample quantities, short turnaround times, and standardized analysis become important alongside analytical performance.
However, market adoption depends on more than instrument specifications.
Relevant factors include:
- Regulatory approvals in each country
- Reimbursement policies
- Laboratory accreditation and certification requirements
- Testing volumes
- Reagent pricing
Furthermore, a manufacturer's claim of results in as little as 24 hours in a research workflow should not automatically be interpreted as the reporting time for every clinical application.
6.3 AI-Driven Improvements in Drug Discovery and Laboratory Operations
At its 2026 Investor Day, Thermo Fisher explicitly identified AI as an important growth enabler. [5]
Management described AI as a technology that could improve customers' drug discovery productivity while also supporting internal operational improvements through PPI.
For Thermo Fisher, the most direct opportunities may lie less in developing foundation models themselves and more in applying AI across its existing products and services.
Potential applications include:
- Multiomics data analysis and interpretation
- Data processing for mass spectrometry and electron microscopy
- Automation of sample preparation and experimental workflows
- Quality control, anomaly detection, and predictive maintenance
- Improvements in clinical trial data quality and operational efficiency
If AI reduces data analysis costs, researchers may be able to conduct more experiments and analyze more samples.
This could increase demand for reagents, instruments, and services.
However, the net impact on revenue is not necessarily positive.
For example, if AI-driven reductions in research and development spending exceed the increase in experimental demand, the financial benefits for suppliers could be limited.
7. Competitive Landscape and Business Risks
One of Thermo Fisher's challenges is determining how effectively it can compete with specialized companies that have strong positions in individual technology markets.
7.1 Major Competitors
| Competitors | Competitive area | Key challenges for Thermo Fisher |
|---|---|---|
| Illumina, MGI Tech | Large-scale NGS | Differentiation beyond throughput and price |
| Oxford Nanopore Technologies, PacBio | Long-read sequencing | Addressing structural variants and complex genomic regions |
| Roche, QIAGEN | Molecular diagnostics and automation | Clinical adoption and regulatory requirements |
| Bruker, Waters | Mass spectrometry | Sensitivity, throughput, analysis software |
| SomaLogic-related technologies and MS companies | High-multiplex proteomics | Reproducibility, coverage, measurement cost |
| Danaher, Sartorius | Bioprocessing | Customer relationships, manufacturing capabilities, product quality |
Although Thermo Fisher owns a broad range of technologies, it competes with specialized companies in each market.
A large overall business does not necessarily imply technological leadership in every individual category.
7.2 Dependence on Research and Development Budgets
If funding for universities and public research institutions declines, purchases of research instruments may be postponed.
Similarly, a weaker financing environment for biotechnology companies can reduce capital investment and research spending.
Thermo Fisher's diversified business model provides some protection, but it does not make the company completely independent of changes in research and development investment.
7.3 Integration of Major Acquisitions
Acquisitions such as Olink and Clario must generate more than technological synergies.
They also need to contribute to revenue growth and profitability.
Even when an acquired company has valuable technologies, integrating those capabilities into a larger organization does not automatically produce sufficient financial returns.
7.4 China and Geopolitical Risks
The international laboratory equipment market is influenced by procurement policies, export restrictions, domestic competitors, and other geopolitical factors.
Competitive developments in China are also relevant to Thermo Fisher's future business environment.
7.5 Regulation of Clinical Genomics
Regulatory requirements differ depending on the intended use of a test.
High technical performance in a research setting does not guarantee widespread clinical adoption.
Regulatory approval, laboratory quality management, and health economics are all important considerations.
7.6 Portfolio Restructuring
In the third quarter of 2026, Thermo Fisher also announced the completion of the sale of its microbiology business. [3]
This illustrates that the company's strategy is not simply to expand into more business areas.
It is also actively reshaping its portfolio.
8. Three Scenarios for 2027–2030
Based on Thermo Fisher's stated strategic priorities and the technological trends discussed above, three potential scenarios can be considered for the 2027–2030 period.
These are qualitative scenarios based on public information, not official financial forecasts or estimates of their probabilities.
8.1 Base Scenario: Expansion as an Integrated Research, Diagnostics, and Manufacturing Platform
In this scenario, Thermo Fisher continues to grow by strengthening its existing diversified business structure.
- Olink captures growth in multiomics research.
- Ion Torrent expands its applications in targeted clinical genomics.
- Clario and PPD strengthen the company's clinical development services.
- Biopharmaceutical manufacturing and consumables provide a stable revenue foundation.
Under this scenario, participating in multiple stages of customers' research and development activities becomes more important than achieving overwhelming market share in a single technology category.
8.2 Upside Scenario: Proteomics Becomes a Major New Growth Engine
In this scenario, the expansion of large-scale proteomics and its translation into clinical applications accelerates.
- Proteome measurements become widely adopted in large cohort studies.
- Biomarkers for disease prediction and treatment response demonstrate clinical utility.
- Olink and Orbitrap become standard options across discovery and validation workflows.
- Integrated research and clinical data generate new forms of customer value.
A particularly important question is whether proteomics can evolve from a research-oriented discovery technology into an approach that meaningfully supports clinical decision-making.
8.3 Downside Scenario: Commercialization of High-Growth Technologies Falls Behind Expectations
Even with a diversified business portfolio, commercialization in emerging growth areas may progress more slowly than anticipated.
- Thermo Fisher's relative competitiveness in NGS instruments declines.
- Proteomics measurement prices fall rapidly.
- Financial synergies from large acquisitions fall short of expectations.
- Reduced research budgets and intensifying competition in China constrain growth.
In this scenario, the company's large scale would not necessarily be sufficient to maintain high growth rates.
9. What Should Genomics Experts Monitor?
To determine whether Thermo Fisher's technology strategy is succeeding, monitoring consolidated revenue alone is insufficient.
It is also important to follow indicators that reflect adoption, technical performance, and commercialization of individual technologies.
| Area | Key performance and technology indicators |
|---|---|
| Ion Torrent / Genexus | Installed base, utilization rates, reagent consumption, turnaround time per test, failure rates |
| Oncomine | Clinical assay panels, IVD approvals, actual clinical testing volumes |
| Olink | Adoption in large-scale studies, cost per sample, reproducibility of protein measurements |
| Orbitrap | Proteome depth in DIA workflows, throughput, quantitative accuracy |
| Multiomics | Externally validated disease biomarkers, integration of pQTL and clinical data |
| Clario / PPD | Organic growth after acquisition, expansion of clinical trial customer contracts |
| Overall company | Organic growth, revenue mix of consumables and services, operating margins, acquisition returns |
Some of these indicators are not disclosed separately in public financial reports.
For example, Ion Torrent's specific market share or Olink's latest standalone revenue cannot be accurately inferred from the overall results of Life Sciences Solutions.
It is therefore necessary to examine additional evidence, including:
- Product-level adoption trends
- Use of technologies in scientific publications
- Clinical implementation of assays
- Management commentary during earnings calls
When evaluating a technology company's strategy, revenue and installed instrument numbers are important, but so is the actual value created in research and clinical settings.
10. Overall Assessment: Where Is Thermo Fisher Heading?
Thermo Fisher's current position and future strategy can be evaluated from three perspectives: NGS, multiomics, and the broader life sciences industry.
10.1 Assessment as an NGS Company
Competition in NGS remains intense.
Nevertheless, Thermo Fisher has opportunities to differentiate itself through targeted NGS, molecular diagnostics, and automated workflows.
In particular, for clinical testing using Genexus and Oncomine, laboratory efficiency and standardization may be more important than raw sequencing capacity.
Leadership in the WGS market is not a prerequisite for Thermo Fisher's overall growth.
10.2 Assessment as a Multiomics Company
Owning both Olink and Orbitrap represents a significant strategic asset.
Proteomic analysis that connects genomic information with actual disease states is a promising growth area.
In particular, the combination of large-scale human cohort proteomics with genomic and longitudinal clinical data could create new opportunities in disease biology and biomarker development.
10.3 Assessment as a Life Sciences Company
Thermo Fisher's greatest strength is its diversified business structure spanning research reagents and instruments, CRO services, contract development and manufacturing organization (CDMO) capabilities, and clinical data.
Even if its competitive position weakens in an individual technology market, it may still capture growth elsewhere in the pharmaceutical and life sciences value chain.
The key to understanding Thermo Fisher's future is therefore not simply asking, "What comes after sequencing?"
A more important question is:
"Which measurement technologies, data resources, and services will be required to translate genomic information into biological understanding and clinical value?"
From a genomics perspective, the following strategic areas deserve particular attention:
- Expansion of human proteomics through Olink and Orbitrap
- Evolution of clinical NGS workflows through Genexus and Oncomine
- Integration of genomic, proteomic, and longitudinal clinical data
- Business synergies across biopharmaceutical research, development, and manufacturing
This ordering reflects their relevance to genomics, rather than a quantitative forecast of their contributions to Thermo Fisher's consolidated revenue growth.
Overall, Thermo Fisher is no longer competing solely through technologies that generate genomic sequence data.
It is evolving into a company that supports the entire process of translating genomic information into disease understanding, molecular diagnostics, drug discovery, clinical development, and pharmaceutical manufacturing.
Over the coming years, a key question will be how effectively the company connects its advancing proteomics capabilities through Olink and Orbitrap, its automated clinical genomics workflows through Genexus, and its expanding clinical development businesses through Clario and PPD.
The answer will help determine whether Thermo Fisher can establish a durable competitive position in the next phase of the life sciences industry.
References
[1] Thermo Fisher Scientific, “Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights,” Press Release, October 29, 2025. https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-to-Acquire-Clario-Holdings-Inc--Enabling-Pharma-and-Biotech-Customers-to-Accelerate-Innovation-with-Deeper-Clinical-Insights/default.aspx
[2] Thermo Fisher Scientific, “Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.,” Press Release, March 24, 2026. https://www.sec.gov/Archives/edgar/data/97745/000009774526000066/a03242026_thermofisherscie.htm
[3] Thermo Fisher Scientific, “Thermo Fisher Scientific Reports Third Quarter 2026 Results,” Earnings Release, October 21, 2026. https://ir.thermofisher.com/investors/news-events/news/news-details/2026/Thermo-Fisher-Scientific-Reports-Third-Quarter-2026-Results/default.aspx
[4] Thermo Fisher Scientific, “Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2025,” U.S. Securities and Exchange Commission, 2026. https://www.sec.gov/ixviewer/ix.html?doc=%2FArchives%2Fedgar%2Fdata%2F97745%2F000009774526000018%2Ftmo-20251231.htm
[5] Thermo Fisher Scientific, “Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day,” Press Release, May 20, 2026. https://ir.thermofisher.com/investors/news-events/news/news-details/2026/Thermo-Fisher-Scientific-Highlights-Industry-Leadership-Growth-Outlook-and-Long-Term-Value-Creation-at-2026-Investor-Day/default.aspx
[6] Thermo Fisher Scientific, “Ion Torrent Genexus System,” Product Information. https://www.thermofisher.com/jp/ja/home/life-science/sequencing/next-generation-sequencing/instruments/genexus-system.html
[7] Thermo Fisher Scientific, “Oncomine Precision Assay,” Product Information, Thermo Fisher Scientific. https://www.thermofisher.com/
[8] Thermo Fisher Scientific, “Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period,” Press Release, July 10, 2024. https://www.sec.gov/Archives/edgar/data/1835539/000095015724000973/ex99-a5w.htm
[9] Mayo Clinic, “Mayo Clinic and Thermo Fisher Scientific Launch Precure, LLC to Identify Signs of Disease Before Symptoms Appear,” Press Release, September 15, 2026. https://www.prnewswire.com/news-releases/mayo-clinic-and-thermo-fisher-scientific-launch-precure-llc-to-identify-signs-of-disease-before-symptoms-appear-302878316.html